NCT00818844已完成4 期
Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Macular thickness
研究概览
简要总结
The purpose of this study is to compare the macular volume of patients treated with a 3-month course of topical Nepafenac (0.1% solution) to patients treated with a placebo course following epiretinal membrane surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 year of age or older, of any race and either sex.
- •Able to understand and sign an informed consent that has been approved by an Institutional Review Board.
- •Must agree to comply with study visit schedule and other study requirements.
- •Must have vision loss associated with idiopathic epiretinal membrane and secondary retinal edema.
- •Must have pre-operative central foveal thickness greater than 300 microns.
- •Prior cataract surgery must be at least 6 months postoperative.
- •Other protocol-defined inclusion criteria may apply.
排除标准
- •Vision loss associated with maculopathies other than idiopathic epiretinal membrane and secondary retinal edema (e.g. branch retinal vein occlusion, central retinal vein occlusion, wet macular degeneration, diabetic retinopathy, posterior uveitis).
- •Dry macular degeneration (drusen) with central geographic atrophy.
- •Concomitant cataract surgery performed at the time of study vitrectomy.
- •Prior vitrectomy surgery in the study eye(s).
- •Prior macula laser treatment in the study eye(s).
- •Prior periocular steroid injections in the study eye(s) within preceding 6 months.
- •Prior cataract surgery in the study eye(s) within the last 6 months.
- •Any systemic or ocular disease or disorder, complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study.
- •Use of topical ocular medications during the study period.
- •Antibiotics (systemic or topical) outside of study protocol may not be used within 7 days of preoperative/baseline visit or anytime after this visit for the duration of the study.
- •Women of childbearing potential not using reliable means of birth control.
- •Women who are pregnant or lactating.
- •Enrollment of more than one person per household at the same time.
- •Enrollment of the investigator or his or her staff, family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.
- •Participation in any investigational drug or device study within 30 days of entering this study. Note: Patients may have both eyes enrolled in this study provided that 2nd eye enrollment takes place 30 days after completion of the first eye. Second eye will receive the same study treatment as first eye.
- •Other protocol-defined exclusion criteria may apply.
研究组 & 干预措施
Nepafenac
Experimental
Nepafenac 0.1% dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
干预措施: Nepafenac 0.1% (Drug)
BSS
Placebo Comparator
BSS dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
干预措施: BSS (Other)
结局指标
主要结局
Macular thickness
时间窗: 12 weeks post operative
Macular thickness as measured by SD-OCT
次要结局
- Visual Acuity(3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract SurgeryCataractNCT00333255Alcon Research267
终止
2 期
Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal PhotocoagulationMacular ThickeningMacular EdemaNCT00801905Asociación para Evitar la Ceguera en México50
尚未招募
Unknown
Effect of non steroidal anti-inflammatory eye drop(nepafenac) on eye(choroidal thickness) of diabetic patients without retinopathy (an end organ damage affecting eye) following cataract surgeryCTRI/2024/05/066781nil
终止
3 期
Macular Edema Incidence/Severity Reduction With NevanacDiabetic RetinopathyNCT00939276Alcon Research175
已完成
2 期
Nepafenac 0.3% Two StudyCataractNCT01318499Alcon Research1,342